Investors with a short time horizon and low tolerance for risk may want to avoid the group, but the patient and the bold may well be rewarded over time.
After a five-week rally, stocks face one of their toughest challenges yet - a very nasty earnings season.
A number of takeover rumors have been making the rounds, an encouraging sign that capitalistic optimism is returning to the markets.
OptionMonster Jon Najarian reveals where he's spotted some unusually bullish action.
Both Pete and Jon Najarian are seeing some unusual options action. What do they make of it?
The OptionMonster is seeing unusual action in two stocks. What does he make of it?
Plus, Whirlpool cycles up and suggested changes to the Dow Jones constituent list.
The president’s budget changes sent stocks tumbling, some undeservedly so.
Amid the gloom, Birinyi Associates' Cleve Rueckert found what he sees as a bright spot in the stock market. In a note, he says growth is the place to be, based on performance of the S&P's Pure Growth Index versus the S&P Pure Value Index. Here's his list of 15 stocks in the S&P 500 that fit three key growth criteria.
Cramer makes the call on viewers' favorite stocks.
A wash of earnings news and weekly jobless claims will help decide the market's course Thursday, but there's a good chance there will be follow through to Wednesday's rally.
Pharmaceutical stocks were winners today on the earnings front, and CNBC guests say they can be winners on the portfolio front as well.
J.P. Morgan analysts today though came up with some names, in a note titled "The Franchise 16 - Stocks to own beyond the market turmoil." They see these as core investments for the next 12 to 18 months.
The Dow fell Tuesday as Congress spent the day bickering over the Wall Street bailout. Also, after hours we learned Warren Buffett is buying Goldman shares.
Twice each year, Standard and Poor's runs a stock screen, designed to find stocks that Warren Buffett might find attractive based on his general investment philosophy. The new list has just been released. Guess what well-known name is missing this time around. (Pay no attention to the picture on the left.)
Baxter researchers unveiled positive mid-stage test results on an intravenous drug, Wednesday, which is already in late-stage development in a very small number of patients.
To help investors prepare their portfolios before the weekend, CNBC asked the experts for their best trades now.
Ed Sheidlower is avoiding financials. But the Bryce Capital Management portfolio manager sees other sectors -- and stocks -- as good investments.
To give investors an edge, CNBC asked the experts for their best stock picks now.
You’ve gotta’ love modern medicine. Not only does it cure stomach upset now it may be the best remedy for what ails your portfolio.